J&J is the textbook blue chip stock -- but it's not for everyone.Investing comes in many flavors, so there isn't a right or wrong approach: You should do what's best for you. That applies even to dividend investing. For some, dividend investing means maximizing immediate income, even if it requires sacrificing some growth and long-term upside; for others, it's the opposite.Healthcare juggernaut Johnson & Johnson (JNJ 0.25%) is a hallowed name in the dividend community, both for its brand recognition and for ...

blackred FOMO (fear of missing out) is hard to ignore when it comes to buying stocks in today's market, especially when influencers post headline-making comments about meme stocks like GameStop (GME) or when expensive stocks just keep going up, as in the case of Nvidia (NVDA), whose market cap just surpassed that of Microsoft (MSFT) to become the world's most valuable company. I'm not bothered, however, by not participating in the aforementioned stock rallies as I'm happy to layer into discounted divide ...

Johnson & Johnson (JNJ) announced that it has submitted a supplemental biologics license application (sBLA) seeking approval of its immunology drug, Tremfya, for a new indication — moderately to severely active Crohn’s disease (CD). This marks the second label expansion filing for Tremfya in three months, following the sBLA in active ulcerative colitis (UC) indication that was filed in March.Tremfya is currently approved to treat certain patients with plaque psoriasis and active psoriatic arthritis in sever ...

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programsTREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) induction, and has the potential to be the first in its class to offer the option of both SC and IV induction therapy in Crohn's diseaseGALAXI includes data demonstrating superior outcomes for TREMFYA® versus STELARA® (ustekinumab) in Crohn's diseaseSPRING HOUSE, Pa., June 20, 2 ...

Key Findings from the GRAVITI Study - The Phase 3 GRAVITI study of TREMFYA® (guselkumab) achieved all primary and secondary endpoints, demonstrating statistically significant and clinically meaningful outcomes for clinical remission and endoscopic response at Week 12 in adult patients with moderately to severely active Crohn's disease [1] - The study also showed significant results for secondary endpoints at Weeks 24 and 48 compared to placebo, reinforcing the potential of TREMFYA® as a treatment option for Crohn's disease [1] - TREMFYA® is positioned to be the only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, providing versatility for patients and healthcare providers [1] About the GRAVITI and GALAXI Programs - The GRAVITI program is a randomized, double-blind, placebo-controlled Phase 3 study evaluating guselkumab SC induction therapy (400 mg at Weeks 0, 4, and 8) in patients with Crohn's disease who had inadequate response to conventional or biologic therapies [3] - The GALAXI program includes Phase 2 and Phase 3 studies (GALAXI 1, 2, and 3) designed to evaluate the efficacy and safety of guselkumab in Crohn's disease patients, with long-term extension studies assessing outcomes over five years [4] About Crohn's Disease - Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract affecting approximately 3 million Americans and 4 million Europeans, with symptoms including abdominal pain, diarrhea, and weight loss [5][6] - The disease has no known cure and is associated with immune system abnormalities potentially triggered by genetic, dietary, or environmental factors [5][6] About TREMFYA® (guselkumab) - TREMFYA® is a fully-human, dual-acting monoclonal antibody that blocks IL-23 by binding to its p19 subunit and CD64, a receptor on IL-23-producing cells [7] - It is approved in multiple countries for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis, with ongoing studies for ulcerative colitis and Crohn's disease [7] About STELARA® (ustekinumab) - STELARA® is an IL-12 and IL-23 antagonist approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in the United States [13] - It is marketed exclusively by the Janssen Pharmaceutical Companies of Johnson & Johnson [13] About Johnson & Johnson - Johnson & Johnson focuses on healthcare innovation, aiming to prevent, treat, and cure complex diseases through its expertise in Innovative Medicine and MedTech [25] - The company is committed to delivering personalized healthcare solutions and driving breakthroughs in the industry [25]

Loading...Loading...As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-time highs, investors are out bargain hunting.Mega-cap stocks, known for their large market capitalizations and relatively stable performances, are often considered safe havens during uncertain times. However, even within this category, there are bargains to be found. Moreover, even in times wh ...

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatmentsVIENNA, June 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa scor ...

24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 studyMADRID, June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable ...

Johnson & Johnson Conference Call Summary Company Overview - **Company**: Johnson & Johnson (NYSE: JNJ) - **Event**: Goldman Sachs 45th Annual Global Healthcare Conference Call - **Date**: June 12, 2024 Key Points Company Transformation and Strategy - Johnson & Johnson has undergone a transformation to focus solely on healthcare, separating its consumer business from its pharmaceutical and medical device operations [7][8] - The company aims to leverage its resources to tackle significant healthcare challenges and is excited about launching new medicines in the near future [9] Financial Performance and Market Position - The company generates approximately 55% of its revenue from North America and 45% from international markets [11] - Johnson & Johnson believes it is well-positioned to weather industry changes due to its diversified business model [11][12] - The company anticipates a 7% growth rate from 2025 to 2035, with over 10 brands expected to exceed $5 billion in peak sales potential [14] Impact of Legislation - The Inflation Reduction Act (IRA) is viewed negatively by Johnson & Johnson, as it is believed to hinder innovation and patient access [12] - Key products like XARELTO and STELARA are expected to be impacted by the IRA, but these products are not seen as primary growth drivers moving forward [13] International Market Outlook - Johnson & Johnson is the number one pharmaceutical company in Europe, with a strong innovative portfolio and access for patients [16] - The company sees growth opportunities in China, which is a top 10 market for them, despite lower pricing due to national drug listings [19] Research and Development - The company has a robust R&D pipeline with a 90% success rate across all phases [24] - Johnson & Johnson is focusing on innovative therapies, including bispecific antibodies and CAR T-cell therapies, to change the practice of medicine [26][51] Product Highlights - The multiple myeloma franchise, including DARZALEX and CARVYKTI, is highlighted as a significant growth area [36] - TREMFYA is expected to perform well in the ulcerative colitis market, with strong data supporting its efficacy [39] - JNJ-2113, an oral peptide inhibitor, is anticipated to unlock opportunities for patients who struggle with existing therapies [43] Neuroscience and Depression Treatments - SPRAVATO has shown significant growth, driven by its profile and provider access [52][55] - Johnson & Johnson is also developing new mechanisms for treating depression, aiming to address treatment-resistant cases [57] Alzheimer's Disease Research - The company is exploring both monoclonal antibodies and a potential vaccine targeting tau proteins to address Alzheimer's disease [58][59] Market Positioning and Future Outlook - Johnson & Johnson is committed to being first-in-class or best-in-class in its therapeutic areas, avoiding following competitors without a unique mechanism [61][62] - The TARIS device for bladder cancer is expected to be a game changer, addressing a high unmet need in the market [64] Additional Insights - The company emphasizes the importance of integrating AI and data analytics across its operations to enhance efficiency and effectiveness in clinical development and commercial strategies [29][31] - Johnson & Johnson's approach to innovation is characterized by a focus on end-to-end therapeutic areas, ensuring seamless transitions from research to market [25]

Johnson & Johnson (NYSE:JNJ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 12, 2024 2:00 PM ET Company Participants Jennifer Taubert - Executive Vice President, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's get started. Thank you, everybody who's here. It's not exactly the weather and climate environment, it's been a big challenge here. Chris Shibutani from the Gol ...